- Previous Close
13.19 - Open
12.80 - Bid --
- Ask --
- Day's Range
12.80 - 13.20 - 52 Week Range
7.93 - 15.70 - Volume
100 - Avg. Volume
146 - Market Cap (intraday)
1.125B - Beta (5Y Monthly) 0.07
- PE Ratio (TTM)
-- - EPS (TTM)
-1.49 - Earnings Date Mar 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
www.liquidia.comRecent News: LT4.F
View MorePerformance Overview: LT4.F
Trailing total returns as of 3/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LT4.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LT4.F
View MoreValuation Measures
Market Cap
1.13B
Enterprise Value
939.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
67.88
Price/Book (mrq)
10.97
Enterprise Value/Revenue
65.32
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.28%
Return on Equity (ttm)
-150.73%
Revenue (ttm)
15.61M
Net Income Avi to Common (ttm)
-119.47M
Diluted EPS (ttm)
-1.49
Balance Sheet and Cash Flow
Total Cash (mrq)
204.37M
Total Debt/Equity (mrq)
104.81%
Levered Free Cash Flow (ttm)
-53.61M